Today, ATAI Life Sciences, a global biotech platform that envisions an end to mental illnesses, announced the appointment of Dr. Terence Kelly as Chief Executive Officer of Perception Neuroscience, an ATAI biopharmaceutical company developing arketamine for treatment resistant depression.
Terence Kelly appointed CEO of ATAI platform company Perception Neuroscience
atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs
BERLIN and BRISBANE, Australia, July 28, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (“atai” or the “Company”) (Nasdaq: ATAI), a clinical-stage biopharmaceutical company…
JOIN THE ATAI #INSIGHTNETWORK